Navigation Links
Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis
Date:11/6/2011

a maximum of 20 weeks passed without reaching this goal (unsuccessful tapering of steroids)[1]. In Part II of the study, patients were randomized to either continue receiving ACZ885, or to receive placebo every 4 weeks, until a pre-specified number (37) of flare-events ("flares") had occurred[1].

The primary endpoints were to: a) assess if ACZ885 allows tapering of steroids in at least 25% of SJIA patients (Part I); and b) demonstrate that time to next flare is extended with ACZ885 vs. placebo (Part II)[1].

In Part I of the study (representing 58 patient years), 138 of 177 patients (78%) reported an adverse event (AE), with the most common being nasopharyngitis, headache and cough. Serious adverse events (SAEs) were reported in 15 patients, with the most common being infections, MAS (four cases) or flare-associated events[1]. Five SAEs led to discontinuation, and one patient died of MAS[1]. During Part II, AEs (the most common being arthralgia, cough, nasopharyngitis and pyrexia) were reported by 40 of 50 (80%) ACZ885-treated patients (vs. 35 of 50 [70%] placebo patients previously treated with ACZ885)[1]; and six patients in each arm experienced one or more SAE, which mainly included infections, MAS and flare-associated events[1]. Six patients, all in the placebo arm, discontinued the study due to AEs or SAEs during Part II[1]. One patient died from MAS after study discontinuation in the placebo group.

MAS is a potentially fatal condition known to be associated with SJIA and is characterized by liver abnormalities, bleeding disorders, central nervous system dysfunction and multiple organ failure[4]. Approximately 10% of SJIA patients are diagnosed with MAS, some of whom suffer repeated episodes[4].

About ACZ885ACZ885 is a fully human monoclonal antibody that inhibits IL-1 beta, which is an important part of the body's immune system defenses. Excessive production of IL-1 beta plays a major role in certain inflammatory d
'/>"/>

SOURCE Novartis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
2. Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe
3. Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder
4. Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
5. Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US
6. Novartis/Schering-Ploughs Drug Will Replace AstraZenecas Symbicort as Decision Resources Clinical Gold Standard by 2012 for the Treatment of Asthma
7. Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD
8. Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure
9. Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR(TM) Technology and Generate Novel Drug Leads Against a GPCR Target
10. Novartis Class Awarded $250 Million in Punitive Damages
11. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Tenn. (PRWEB) July 29, 2014 ... in biomass feedstock supply innovation and supply chain ... proprietary feedstock management systems, Energy Grange™ and Supply ... of R&D and in-the-field testing aimed at consolidating ... offering benefits to landowners, farmers and feedstock end ...
(Date:7/29/2014)... SPRING, Md., July 29, 2014  United Therapeutics ... announced its financial results for the second ... continued growth shows that our medicines are ... pulmonary arterial hypertension (PAH)," said Martine Rothblatt, ... Officer. "The commercial launch this quarter of ...
(Date:7/29/2014)... MA (PRWEB) July 29, 2014 The ... Library of Congress was recently awarded to Juliana Hillis ... Stoneham, MA, for their project, “From an Egg, Everything: ... among 3,000 final entries for the National History Day ... than 300 historians and educators in Washington, D.C. , ...
(Date:7/29/2014)... , July 29, 2014 ... Biopsy System (LBS) zur Erfassung biologischer Daten ... Herzkranzgefäßen entwickelt und patentiert. Das LBS nimmt ... der Koronararterie des Patienten und sucht erhöhte ... hat das Potenzial, die Entdeckung und Entwicklung ...
Breaking Biology Technology:Genera Energy Introduces Proprietary Feedstock Management Systems 2Genera Energy Introduces Proprietary Feedstock Management Systems 3Genera Energy Introduces Proprietary Feedstock Management Systems 4United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 11United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 12United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 13In Vitro Fertilization (IVF) was the Subject of This Year’s Winning Entry for the Prestigious Library of Congress “Discovery or Exploration in History Award” 2In Vitro Fertilization (IVF) was the Subject of This Year’s Winning Entry for the Prestigious Library of Congress “Discovery or Exploration in History Award” 3PlaqueTec sichert sich CE-Kennzeichnung für Liquid Biopsy System - bahnbrechende Innovation zur Erfassung neuer biologischer Informationen aus erkranktem Herzkranzgefäß 2PlaqueTec sichert sich CE-Kennzeichnung für Liquid Biopsy System - bahnbrechende Innovation zur Erfassung neuer biologischer Informationen aus erkranktem Herzkranzgefäß 3PlaqueTec sichert sich CE-Kennzeichnung für Liquid Biopsy System - bahnbrechende Innovation zur Erfassung neuer biologischer Informationen aus erkranktem Herzkranzgefäß 4
... 3, 2011 MAP Pharmaceuticals, Inc. (Nasdaq: MAPP ... March 31, 2011. The net income for the ... to a net loss of $14.1 million during the same ... March 31, 2011 was related primarily to the $34.2 million ...
... May 2, 2011 Anadys Pharmaceuticals, Inc. (Nasdaq: ... 2011 financial results on Thursday, May 5, 2011, after the ... conference call and webcast on Thursday, May 5, 2011 at ... 2011 financial results and highlights and to provide an update ...
... WAGENINGEN, Netherlands, May 2, 2011 Dyadic International, ... company focused on the discovery, development, manufacture and ... biopharmaceutical, biofuels and industrial enzyme industries, announced today ... B.V. ("Dyadic Netherlands"), has entered into a research ...
Cached Biology Technology:MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results 2MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results 3MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results 4MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results 5Anadys Pharmaceuticals to Report First Quarter 2011 Financial Results 2Dyadic Netherlands Enters Into R&D Collaboration With Sanofi Pasteur and EnGen Bio 2
(Date:7/29/2014)... news for parents of preterm babies latest research from ... time they become teenagers, the brains of many preterm children ... , A study conducted by the University,s Robinson Research ... child experiences no brain injury in early life, their cognitive ... their term-born peers. , However, the results of the study, ...
(Date:7/28/2014)... drugs already approved by the U.S. Food and Drug ... growth of certain bacterial pathogens inside human cells, including ... fever. The findings, published in mBio , the ... demonstrate a new way of identifying non-antibiotic drugs that ... A handful of drugs on the list inhibit the ...
(Date:7/28/2014)... TEMPE, Ariz. - Reactions among minerals and organic compounds ... deep carbon cycle, they provide energy for the deep ... life. However, very little is known about how minerals ... Arizona State University have demonstrated how a common mineral ... negating the need for toxic solvents or expensive ...
Breaking Biology News(10 mins):Preterm children's brains can catch up years later 2New route to identify drugs that can fight bacterial infections 2Mineral magic? Common mineral capable of making and breaking bonds 2Mineral magic? Common mineral capable of making and breaking bonds 3
... Springer will publish The HUGO Journal in cooperation ... Springer as Genomic Medicine, The HUGO Journal has ... Members of HUGO will receive free access to the ... discounted rates. The HUGO Journal will focus ...
... announced today that its Ewell Sale Stewart Library has ... Heritage Library. The BHL is a group of 12 ... worldwide dedicated to digitizing the published literature on biodiversity ... more widely available. Scanning and cataloguing the materials preserves ...
... New evidence for ice-free summers with intermittent winter sea ... a period of greenhouse conditions - gives a glimpse of ... warming. Records of past environmental change in the Arctic ... period between 100 and 65 million years ago leading up ...
Cached Biology News:Academy Library accepted to prestigious Biodiversity Heritage Library 2Arctic climate under greenhouse conditions in the Late Cretaceous 2Arctic climate under greenhouse conditions in the Late Cretaceous 3
... serum biomarker chip to profile the relative ... chip containing 120 human cancer serum biomarker-specific ... discovery scientists to study panels of biomarkers ... and the likelihood of recurrence of cancer. ...
... is a highly sensitive reagent for the ... a purified form of recombinant E. coli ... which is sensitive to changes in its ... Phosphate Sensor is rapid and tight (Kd ...
... fume hood ventilates and purifies ... release of exhaust. Bonded charcoal ... Configurations are available with vertical ... final HEPA filter, work bench ...
Sigmas E-TOXATE (Limulus Amebocyte Lysate) test kits are intended for the detection and semiquantitation,of endotoxins for research purposes....
Biology Products: